Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Optic nerve diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Optic nerve diseases. Displaying page 4 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2014-000395-26 Sponsor Protocol Number: GER-BGT-13-10586 Start Date*: 2015-08-07
    Sponsor Name:Biogen GmbH
    Full Title: A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003083-31 Sponsor Protocol Number: Becro/OV/Brimo Start Date*: 2013-10-17
    Sponsor Name:OmniVision GmbH
    Full Title: Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of Brimonidine 2 mg...
    Medical condition: Open angle glaucoma or ocular hypertension.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.1 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002529-12 Sponsor Protocol Number: CICL670F2203 Start Date*: 2017-10-19
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multicenter, open-label, randomized two-year study to evaluate the efficacy and safety of deferasirox film-coated tablet versus phlebotomy in patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012236 10057874 Hereditary hemochromatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Completed) DE (Completed) BE (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-001215-37 Sponsor Protocol Number: RG_16_211 Start Date*: 2018-03-19
    Sponsor Name:University of Birmingham
    Full Title: A pivotal, international, randomised, double-blind, efficacy and safety trial of sodium valporate in paediatric and adult patients with Wolfram Syndrome
    Medical condition: Wolfram syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005091-42 Sponsor Protocol Number: 192024-041D Start Date*: 2012-05-08
    Sponsor Name:Allergan Limited
    Full Title: An Open Label (Stage 1) and Randomized (Stage 2), 24-Month Study of Safety and Efficacy of Bimatoprost Drug Delivery System in Patients With Open-Angle Glaucoma or Ocular Hypertension
    Medical condition: open-angle glaucoma (OAG) and ocular hypertension (OHT)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10018307 Glaucoma and ocular hypertension HLGT
    14.1 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.1 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-000642-35 Sponsor Protocol Number: HL217-201 Start Date*: 2019-09-19
    Sponsor Name:HANLIM PHARM CO., LTD
    Full Title: A phase IIa randomized, double-blind, multicentre study to evaluate safety and efficacy of HL217 topical ophthalmologic solution in the treatment of exudative Age-Related Macular Degeneration (AMD)
    Medical condition: AMD (age-related macular degeneration)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10068530 Macular degeneration progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000590-93 Sponsor Protocol Number: CR213-20 Start Date*: 2023-06-09
    Sponsor Name:CuraTeQ Biologics Private Ltd.
    Full Title: A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (N...
    Medical condition: Wet (Neovascular) Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023037-35 Sponsor Protocol Number: LIEPS2010 Start Date*: 2011-05-05
    Sponsor Name:York Teaching Hospital NHS Foundation Trust
    Full Title: Short-term intraocular pressure trends in high risk patients following intravitreal Ranibizumab (Lucentis) injections for Wet Age Related Macular Degeneration - Is there a role for systemic Acetazo...
    Medical condition: Glaucoma and Glaucoma suspect
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10006028 Borderline glaucoma (glaucoma suspect) LLT
    14.1 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004442-10 Sponsor Protocol Number: SPORTII Start Date*: 2015-02-05
    Sponsor Name:UZ Leuven
    Full Title: Intraocular pressure and tolerability Study of Preserved Bimatoprost 0.1% (BMD) or Tafluprost Unit Dose Preservative Free 15microgram/ml (TUDPF) (Saflutan), in patients with Ocular hypertension or...
    Medical condition: Ocular hypertension and glaucoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10030043 Ocular hypertension PT
    17.1 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005339-15 Sponsor Protocol Number: QTM/OMN0211 Start Date*: 2012-02-03
    Sponsor Name:Omnivision GmbH
    Full Title: Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of the Fixed Combin...
    Medical condition: Primary open angle glaucoma or intraocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.0 10015919 - Eye disorders 10036719 Primary open angle glaucoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-002601-30 Sponsor Protocol Number: QTM/OMN0111 Start Date*: 2011-09-26
    Sponsor Name:OMNIVISION GmbH
    Full Title: A COMPARISON OF LATANOPROST 50µg/ml EYE DROPS vs. XALATAN EYE DROPS IN THE TREATMENT OF OPEN ANGLE GLAUCOMA: AN OPEN, RANDOMIZED, CLINICAL TRIAL
    Medical condition: Open angle glaucoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10030856 Open-angle glaucoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-000026-22 Sponsor Protocol Number: QTM/OMN0112 Start Date*: 2012-07-23
    Sponsor Name:Omnivision GmbH
    Full Title: Open, Observer-blind, two Parallel Group, Randomized, Multicentric Clinical Phase III Trial on the Comparison of Efficacy and Tolerability of a New Preservative-free Formulation of Travoprost 40 µg...
    Medical condition: Primary open angle glaucoma or intraocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10030043 Ocular hypertension PT
    14.1 10015919 - Eye disorders 10036719 Primary open angle glaucoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000147-45 Sponsor Protocol Number: YS001 Start Date*: 2021-06-04
    Sponsor Name:YONSUNG GMBH
    Full Title: A non-inferiority, randomized, investigator - masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost (YSLT) vers...
    Medical condition: GLAUCOMA, OCCULAR HYPERTENSION
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024272-26 Sponsor Protocol Number: GLC-05-10 Start Date*: 2011-04-14
    Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
    Full Title: Comparison of the effects of Bimatoprost 0.01% and Timolol 0.5% on circadian intraocular pressure
    Medical condition: glaucoma and ocular hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10030348 Open angle glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002158-35 Sponsor Protocol Number: IVA_01_ODI_HMPS_17_002 Start Date*: 2017-11-16
    Sponsor Name:Inventiva S.A.
    Full Title: A phase IIa study to investigate safety, Pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis (MPS) type VI.
    Medical condition: Mucopolysaccharidosis (MPS) type VI.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10028095 Mucopolysaccharidosis IV PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005090-22 Sponsor Protocol Number: 001 Start Date*: 2012-02-28
    Sponsor Name:Southend Hospital
    Full Title: A study of efficacy and safety of delayed release prednisone in newly diagnosed cases of Giant Cell Arteritis
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003556-31 Sponsor Protocol Number: SHP-607-201 Start Date*: 2015-02-10
    Sponsor Name:Premacure AB, A Member of the Shire Group of Companies
    Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care
    Medical condition: Retinopathy of Prematurity (ROP)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003278-10 Sponsor Protocol Number: 192024-056 Start Date*: Information not available in EudraCT
    Sponsor Name:Allergan Ltd.
    Full Title: A Multicenter, Double-masked, Randomized, Active-controlled, Parallel Study of the Safety and Efficacy of Once-daily Bimatoprost Preservative-free Ophthalmic Solution Compared to Twice-daily Timolo...
    Medical condition: Glaucoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003490-10 Sponsor Protocol Number: ECR-GLC-2013-06 Start Date*: 2013-09-27
    Sponsor Name:AIBILI (EVICR.net)
    Full Title: Intraocular pressure and tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or preservative free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in patients with Ocular h...
    Medical condition: Ocular hypertension and glaucoma.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10015919 - Eye disorders 10030043 Ocular hypertension PT
    16.0 10015919 - Eye disorders 10018304 Glaucoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) PT (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001323-23 Sponsor Protocol Number: CH/2013/4247 Start Date*: 2015-07-03
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A phase II trial of Tocilizumab in anti-TNF refractory patients with JIA associated uveitis.
    Medical condition: Juvenile Idiopathic Arthritis with Associated Uveitis
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10046851 Uveitis PT
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10059176 Juvenile idiopathic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 05:25:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA